Our research program focuses on two areas under the theme of cancer cell signaling and therapeutics.  We emphasize an understanding of the cellular and biochemical properties of signaling proteins, to determine how they are regulated, how they perform their functions and as a basis for designing novel therapeutic strategies to target human cancers.

1) Molecular mechanisms of signal transduction. The altered regulation and function of signaling proteins, such as protein kinases, contribute to the ability of tumors to form and then to grow. Altered signaling also helps cancer cells to survive severe stresses that result from such things as poor oxygenation, altered metabolism and genetic instability.  In addition, aberrant signaling allows cancer cells to avoid the immune system and promotes tumor metastasis.  Our work aims to better understand how changes that may occur to alter a protein’s expression, regulation or sequence facilitate cancer phenotypes.

2) Novel strategies to inhibit aberrant signaling in cancer cells. Drug discovery projects in the laboratory focus on either unique targets or alternative approaches to inhibit validated targets. They may involve assay development, structure-guided chemical synthesis of lead compounds and target validation. Special emphasis is placed on potential mechanisms of resistance.

High Throughput screening facility

http://sites.utexas.edu/ttdddp/

Researchgate Profile and publication downloads

https://www.researchgate.net/profile/Kevin_Dalby

Google Scholar Profile

https://scholar.google.com/citations?user=rG6zU8oAAAAJ&hl=en

Link to NCBI

https://www.ncbi.nlm.nih.gov/myncbi/1daxq7Lap5n/bibliography/public/

Honors Program (Pharmacy)

https://sites.utexas.edu/adrgs/adrgs-office-team/kevin-dalby-ph-d/